A Probody T Cell-Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity.
Leila M BoustanySherry L LaPorteLaurie WongClayton WhiteVeena VinodJoel ShenWendy YuDavid KoditekMichael B WinterStephen J MooreLi MeiLinnea DiepYuanhui HuangShouchun LiuOlga VasiljevaJim WestJennifer RichardsonBryan IrvingMarcia BelvinW Michael KavanaughPublished in: Cancer research (2022)
A conditionally active EGFR-CD3 T cell-engaging Probody therapeutic expands the safety window of bispecific antibodies while maintaining efficacy in preclinical solid tumor settings.